Mild Cognitive Impairment Clinical Trial
Official title:
The Feasibility and Preliminary Effects of an Empowerment-based Cognitive Behavioural Therapy for Insomnia on Sleep, Cognitive Function and Health--related Quality of Life in Persons With Mild Cognitive Impairment
Verified date | November 2023 |
Source | The University of Hong Kong |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Dementia is irreversible, incurable and devastating. It is thus imperative to preserve cognition at the pre-dementia stage. Mild cognitive impairment (MCI) refers to the reversible intermediate clinical state between normal age-related cognitive decline and dementia. Because no pharmacological treatments have proved to be effective, risk factor modification remains the cornerstone in preventing progression from MCI to dementia. Insomnia is an emerging risk factor now being associated with cognitive decline, and it affects up to 59% of persons with MCI. Compelling evidence shows that sleep is vital for memory consolidation, and it mediates the deposition of amyloid-β and tau proteins in the brain. Despite these findings, minimal research has done to evaluate sleep-promoting interventions on the cognitive function of persons with MCI. Non-pharmacological interventions remain the treatment of choice for managing insomnia, particularly the older population. These interventions require individuals to actively participate in the treatment process. Yet, the cognitive impairment and neuropsychiatric symptoms in persons with MCI create challenges for them. An empowerment approach with interactive teaching strategies and experiential learning may be the best method of engaging people in the learning process and arousing their inherent capacity to maintain behavioral modifications. This study aims to examine the feasibility and preliminary effects of an empowerment-based cognitive behavioral therapy for insomnia (CBT-I) in persons with MCI and sleep problems. The researchers will compare the effects of this intervention by comparing with the standard care.
Status | Completed |
Enrollment | 60 |
Est. completion date | April 30, 2022 |
Est. primary completion date | April 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: - aged >=50 years - living in the community - Independence in daily living as evaluated through the clinical interview - Presence of cognitive complaints, defined as >= 3 complaints on the Memory Inventory for Chinese - Abnormal objective cognitive performance defined as <-1.5 standard deviations from age - Education-matched normal persons on the Montreal Cognitive Assessment Hong Kong Version (HK-MoCA) - Persons with poor sleep quality that can be assessed by the Pittsburgh Sleep Quality Index, with a global PSQI score of >5 Exclusion Criteria: - Persons with confirmed dementia - Persons with known psychiatric conditions - Persons with impaired communication - Persons with sleep disorders with an organic cause (e.g., sleep apnea, or restless legs syndrome) or due to a medical problem (e.g., pain) - Persons with the use of hypnotics and other medications known to affect sleep (e.g., steroids, anxiolytics) |
Country | Name | City | State |
---|---|---|---|
Hong Kong | Polly Wai Chi | Hong Kong | Please Select |
Lead Sponsor | Collaborator |
---|---|
The University of Hong Kong |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes from Baseline in Sleep on the 19 item The Pittsburgh Sleep Quality (PSQI) Index at the 12th week and 3 months | The Chinese PSQI is a validated, self-reported instrument for assessing sleep disturbance over the month. A 3-point Likert scale is used to each item (0=no difficulty; to 3 =severe difficulty). Possible total score ranging from 0-21. MCI persons with global score>5 will be eligible for inclusion. | Change from Baseline Chinese PSQI at the 12th week (after the intervention) and 3 months (follow up)] | |
Primary | Changes from Baseline in Insomnia Severity on the 7-item The Chinese version of the Insomnia Severity Index (ISI-C)at the 12th week and 3 months | The ISI-C is a validated, self-reported instrument for assessing the perceived insomnia severity, consequences of insomnia and the degree of distress related to insomnia. A 5-point Likert scale is used to rate each item (e.g., 0 = no problem; 4 = very severe problem), Possible a total score ranging from 0 to 28. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28). | Change from Baseline ISI-C at the 12th week (after the intervention) and 3 months (follow up)] | |
Primary | An Actiwatch, which contains an accelerometer (during sleep for a consecutive seven-day period) | to record the frequency of body movement, will be used to objectively assess sleep patterns automatically. | Change from Baseline the frequency of body movement at the 12th week (after the intervention) and 3 months (follow up)] | |
Primary | An Actiwatch, which contains an accelerometer (during sleep for a consecutive seven-day period) | to record the intensity of body movement, will be used to objectively assess sleep patterns automatically. | Change from Baseline the intensity of body movement at the 12th week (after the intervention) and 3 months (follow up)] | |
Primary | An Actiwatch, which contains an accelerometer (during sleep for a consecutive seven-day period) | To record the sleep parameters include total sleep time (TST), sleep latency (SL), wake after sleep onset (WASO) and the ratio of total sleep time (TST) to sleep efficiency (SE) of sleep, will be used to objectively assess sleep patterns automatically. | Change from Baseline sleep parameters at the 12th week (after the intervention) and 3 months (follow up)] | |
Primary | Changes from the Cantonese version of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) | The ADAS-Cog is a validated instrument for assessing language, memory in order to detect the subtle cognitive changes. The standard ADAS-cog includes the following 11 items, with a possible Total scoring range of 0 - 70. The ADAS score is based on the number of errors made in each item. A score of 70 represents the most severe impairment and 0 represents the least impairment. | Change from Baseline ADAS-Cog at the 12th week (after the intervention) and 3 months (follow up)] | |
Primary | Changes from the Hong Kong List Learning Test (HKLLT) | The HKLLT is a validated instrument for assessing complex attention, executive function and task switching. Participants were required to learn a list of 16 Chinese words through three learning trials. After 10 and 30 min delay, they were asked to recall as many words as possible. The total number of recalled words after a delay was used to reflect verbal memory ability. A low score on Trial 1, with normal performance on Trial 3 and total learning, is considered to reflect problems in auditory attention spam, but intact learning ability. Poor scores on all three learning trials provide evidence for acquisition problems in learning and memory. The T-score range from <20 to >/= 65. The score of >=65 represents superior and <20 represents the severely impaired. | Change from Baseline HKLLT at the 12th week (after the intervention) and 3 months (follow up)] | |
Primary | the Color Trail Test (CCT) | CCT is a validated instrument for assessing complex attention, executive function and task switching. Time taken to complete each part of the CTT is recorded in seconds and is compared to normative data. Qualitative aspects of the performance that may be indicative of brain dysfunction (e.g. near misses, prompts required, sequencing errors for color and number) are also recorded. The CTT manual reports that it takes 3-8 minutes to complete the CTT. A task is discontinued if the client takes longer than 240 seconds to complete it. Performance time <60 seconds on the CTT was found to predict passing the on-road evaluation, whereas >60 seconds was predictive of failing | Change from Baseline the CCT at the 12th week (after the intervention) and 3 months (follow up)] | |
Primary | The Chinese Hong Kong version of the Short Form Health Survey (SF-12) | SF-12 is a validated instrument for assessing the general health of people, both physical and mental well-being. A mental component score and a physical component score are reported as Z-scores (different compared to the population average, 12 are both 50 points). The standard deviation is 10 points, so each 10 increment of 10 points above or below 50, corresponds to one standard deviation away from the average. | Change from Baseline SF-12 at the 12th week (after the intervention) and 3 months (follow up)] |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |